Clinical Trial Update: ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients [Phase 1, Phase 2]

View source ↗

Summary

Update on ESBA1008 in wet age-related macular degeneration assessing safety, tolerability, and preliminary effects in Phase 1/2. The trial is completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• ESBA1008

Snippet

Sponsor: Alcon Research | Conditions: Exudative Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-05-07